Elevated serum osteoprotegerin levels measured early after acute ST-elevation myocardial infarction predict final infarct size

Heart

Volumn 97, Issue 6, 2011, Pages 460-465

  Andersen, Geir Øystein ^a,b   Knudsen, Eva Cecilie ^a,b   Aukrust, Pål ^c,d,e   Yndestad, Arne ^b,c   Øie, Erik ^b,c,f   Müller, Carl ^a   Seljeflot, Ingebjørg ^a,b,e   Ueland, Thor ^c,d  

^a ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

^c OSLO UNIVERSITY HOSPITAL   (Norway)

^d OSLO UNIVERSITY HOSPITAL   (Norway)

^e UNIVERSITY OF OSLO   (Norway)

^f DIAKONHJEMMET HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

OSTEOPROTEGERIN;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION;

AGED; BIOLOGICAL MARKERS; CARDIAC-GATED SINGLE-PHOTON EMISSION COMPUTER-ASSISTED TOMOGRAPHY; EPIDEMIOLOGIC METHODS; FEMALE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; OSTEOPROTEGERIN; PROGNOSIS;

EID: 79952003370     PISSN: 13556037     EISSN: 1468201X     Source Type: Journal    
DOI: 10.1136/hrt.2010.206714     Document Type: Article

References (16)

1. Jono S, Ikari Y, Shioi A, et al. Serum osteoprotegerin levels are associated with the presence and severity of coronary artery disease. Circulation 2002;106:1192-4. (Pubitemid 34988634)
2. Kiechl S, Werner P, Knoflach M, et al. The osteoprotegerin/RANK/RANKL system: a bone key to vascular disease. Exp Rev Cardiovasc Ther 2006;4:801-11. (Pubitemid 46017520)
3. Abedin M, Omland T, Ueland T, et al. Relation of osteoprotegerin to coronary calcium and aortic plaque (from the Dallas Heart Study). Am J Cardiol 2007;99:513-18. (Pubitemid 46215559)
4. Crisafulli A, Micari A, Altavilla D, et al. Serum levels of osteoprotegerin and RANKL in patients with ST elevation acute myocardial infarction. Clin Sci 2005;109:389-95. (Pubitemid 41445246)
5. Ueland T, Jemtland R, Godang K, et al. Prognostic value of osteoprotegerin in heart failure after acute myocardial infarction. J Am Coll Cardiol 2004;44:1970-6. (Pubitemid 39473280)
6. Omland T, Ueland T, Jansson AM, et al. Circulating osteoprotegerin levels and long-term prognosis in patients with acute coronary syndromes. J Am Coll Cardiol 2008;51:627-33. (Pubitemid 351193104)
7. Knudsen E, Seljeflot I, Abdelnoor M, et al. Abnormal glucose regulation in patients with acute ST-elevation myocardial infarction - a cohort study on 224 patients. Cardiovasc Diabetol 2009;8:6.
8. Thygesen K, Alpert JS, White HD, et al. Universal definition of myocardial infarction. Circulation 2007;116:2634-53. (Pubitemid 350182388)
9. Ueland T, Bollerslev J, Godang K, et al. Increased serum osteoprotegerin in disorders characterized by persistent immune activation or glucocorticoid excess - possible role in bone homeostasis. Eur J Endocrinol 2001;145:685-90. (Pubitemid 33133673)
10. Chia S, Senatore F, Raffel OC, et al. Utility of cardiac biomarkers in predicting infarct size, left ventricular function, and clinical outcome after primary percutaneous coronary intervention for ST-segment elevation myocardial infarction. JACC Cardiovasc Interv 2008;1:415-23.
11. Gibbons RJ, Miller TD, Christian TF. Infarct size measured by single photon emission computed tomographic imaging with (99m)Tc-sestamibi: a measure of the efficacy of therapy in acute myocardial infarction. Circulation 2000;101:101-8. (Pubitemid 30039083)
12. Antman E, Bassand J-P, Klein W, et al. Myocardial infarction redefined - a consensus document of the Joint European Society of Cardiology/American College of Cardiology committee for the redefinition of myocardial infarction: the Joint European Society of Cardiology/American College of Cardiology Committee. J Am Coll Cardiol 2000;36:959-69.
13. Sandberg WJ, Yndestad A, Øie E, et al. Enhanced T-cell expression of RANK ligand in acute coronary syndrome: possible role in plaque destabilization. Arterioscler Thromb Vasc Biol 2006;26:857-63.
14. Ueland T, Yndestad A, Øie E, et al. Dysregulated osteoprotegerin/RANK ligand/RANK axis in clinical and experimental heart failure. Circulation 2005;111:2461-8.
15. Collin-Osdoby P. Regulation of vascular calcification by osteoclast regulatory factors RANKL and osteoprotegerin. Circ Res 2004;95:1046-57. (Pubitemid 39557891)
16. Collin-Osdoby P, Rothe L, Anderson F, et al. Receptor activator of NF-kappa B and osteoprotegerin expression by human microvascular endothelial cells, regulation by inflammatory cytokines, and role in human osteoclastogenesis. J Biol Chem 2001;276:20659-72.